Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan for prevention of recurrent C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis after kidney transplantation
2026-526392-39-00Phase 3Authorised
- Sponsor
- Sobi
- Start
- Oct 2026
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of pegcetacoplan in Complement 3 glomerulopathy (C3G) and Primary immune complex membranoproliferative glomerulonephritis (MPGN), sponsored by Sobi. Primary endpoint: Occurrence of clinically significant recurrent disease within 2 years post-kidney transplantation. Planned start Oct 2026; status: authorised.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Primary immune complex membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on 2026-526392-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526392-39-00.